文献速递腹部介入CT

CT引导高剂量率组织间近距离放疗治疗原发性和继发性胰腺恶性肿瘤的疗效与安全性

Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas.
PubMed 文献 · Eur J Radiol · 2018-12-28

单中心纳入13例胰腺体尾部病灶(8例转移瘤、3例原发瘤、2例术后孤立局部复发),行192铱源单次CT引导组织间近距离放疗;中位GTV直径3 cm,中位D100 15.3 Gy;中位随访6.7个月局部肿瘤控制率92.3%,中位PFS 6.2个月,中位OS 16.2个月;1例轻度急性胰腺炎自行缓解,无3级及以上不良事件。

要点

  • 单次192铱源CT引导组织间近距离放疗后局部肿瘤控制率达92.3%。
  • 中位GTV直径3 cm,中位最小包绕肿瘤剂量D100为15.3 Gy。
  • 仅1例出现轻度急性胰腺炎并1周内自行缓解,无3级及以上不良事件。

核心结论

  • 影像引导组织间近距离放疗对原发性和继发性胰腺恶性肿瘤安全且尤其有效,可能为选定患者的多学科管理提供耐受性良好的额外治疗选择。

研究设计与样本

  • 单中心纳入13例患者共13个胰腺体尾部病灶,其中继发性恶性肿瘤8例(转移性病灶)、原发性恶性肿瘤5例(原发肿瘤3例、手术切除后孤立局部复发2例)。
  • 采用192铱源行影像引导组织间近距离放疗,单次分割照射。
  • 治疗后每3个月进行临床和影像随访以评估疗效,围手术期及术后并发症采用描述性评估。

诊断标准与关键数值

  • 局部肿瘤控制率92.3%,中位随访6.7个月(范围3.2–55.7个月)。
  • 中位无进展生存期6.2个月(范围2.8–25.7个月),原发性和继发性恶性肿瘤分别为5.8个月和6.2个月。
  • 组织间近距离放疗后中位总生存期16.2个月(范围3.3–55.7个月),原发性和继发性恶性肿瘤分别为7.4个月和45.6个月。
  • 中位GTV直径3 cm(范围1–6.5 cm),中位D100(最小包绕肿瘤剂量)15.3 Gy(范围9.2–25.4 Gy)。

临床应用与阅片要点

  • 作者认为影像引导组织间近距离放疗安全且尤其有效,可能为选定患者的多学科管理提供耐受性良好的额外治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate efficacy and safety of CT-guided iBT in patients with primary and secondary malignancies of the pancreas.

MATERIAL AND METHODS: 13 patients with 13 lesions of the pancreatic corpus and tail were included: 8 secondary malignancies (metastatic lesions = ML) and 5 primary malignancies, including 3 primary tumors (PT) and 2 isolated locoregional recurrences (ILR) after surgical resection were treated with image-guided iBT using a 192iridium source (single fraction irradiation). Every 3 months after treatment clinical and imaging follow-up were conducted to evaluate efficacy. Peri- and postinterventional complications were assessed descriptively.

RESULTS: The median diameter of the gross tumor volume (GTV) was 3 cm (range 1-6.5 cm), treated with a median D100 (minimal enclosing tumor dose) of 15.3 Gy (range 9.2-25.4 Gy). Local tumor control (LTC) was 92.3% within a median follow-up period of 6.7 months (range 3.2-55.7 months). Cumulative median progression free survival (PFS) was 6.2 months (range 2.8-25.7 months; PFS of primary and secondary malignancies was 5.8 and 6.2 months, respectively). Cumulative median over all survival (OS) after iBT was 16.2 months (range 3.3-55.7 months; OS of primary and secondary malignancies was 7.4 months and 45.6 months, respectively). 1 patient developed mild acute pancreatits post iBT, spontanously resolved within 1 week. No severe adverse events (grade 3+) were recorded.

CONCLUSION: Image-guided iBT is a safe and particularly effective treatment in patients with primary and secondary malignancies of the pancreas and might provide a well-tolerated additional therapeutic option in the multidisciplinary management of selected patients.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Omari J, Heinze C, Wilck A, et al. Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. Eur J Radiol. 2018. PMID: 30777214. doi:10.1016/j.ejrad.2018.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。